Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous XXXX .

@entity1 @entity137 @entity470 @entity1149 @entity3
UNASSIGNED: Compared with other platinum-based doublet chemotherapy, pemetrexed plus platinum is more effective and tolerable as the first-line treatment for nonsquamous @entity1149 ( @entity1149 ). Thus, we examined the feasibility of using thoracic radiotherapy combined with concurrent full-dose pemetrexed as the first-line treatment for advanced nonsquamous @entity1149 @entity1 . From January 2009 to July 2012, 41 @entity1 with stage IIIB or IV nonsquamous @entity1149 were treated with full-dose pemetrexed plus cisplatin as the first-line chemotherapy combined with concurrent thoracic radiotherapy, with or without radiotherapy for @entity3 . The status of mutations in the @entity470 was unknown before the treatment, and no tyrosine-kinase inhibitor and cytotoxic drug maintenance therapy were administered to the @entity1 after the chemotherapy. The median follow-up duration was 26.3 months (range, 5.8-57.5 months). Twenty-one @entity1 had stage IIIB disease (19 with stage N3-IIIB). Of the 20 @entity1 with stage IV disease, 16 had oligometastases ( <=5) and four had polymetastases. The median number of chemotherapy cycles was 4. The median radiation dose was 60   Gy. Thirty-six @entity1 received radical doses of radiotherapy. @entity137 were highly tolerated. The median progression-free survival was 12 months and the median overall survival was 32 months. The 1-, 2-, and 3-year overall survival rates were 87.5, 67.1, and 43.4%, respectively. As the first-line treatment for selected @entity1 with advanced nonsquamous @entity1149 , thoracic radiotherapy combined with concurrent full-dose pemetrexed plus cisplatin was safe and highly tolerable. In addition, the survival rate was encouraging. Prospective clinical trials are needed to verify the results.
